Prevalence of antibodies against hepatitis C virus in Norwegians with congenital coagulation factor defects treated with plasma products from small pools.
The prevalence of antibodies against hepatitis C virus (HCV) in sera from 266 Norwegians with coagulation factor defects of different types and degrees of severity was assessed by an enzyme immunoassay. The overall prevalence was 41%, the highest rates being found in persons with severe hemophilia A (64%) or B (67%). These prevalence rates are below those found in hemophiliacs in most other countries in the Western hemisphere. This may be due to the strategy for coagulation factor substitution used and a favorable epidemiological situation.
Rollag
H
H
Institute of Bacteriology, Rikshospitalet, Oslo, Norway.
Evesen
S A
SA
Fröland
S S
SS
Glomstein
A
A
D001779:Blood Coagulation Factors / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D002836:Hemophilia B / Q000150:complications* / Q000628:therapy; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology*; D006801:Humans; D008297:Male; D009664:Norway / Q000453:epidemiology; D015995:Prevalence; D014842:von Willebrand Diseases / Q000150:complications / Q000628:therapy
D001779:Blood Coagulation Factors; D006508:Hepatitis Antibodies